Colegio Médicos Postgraduados IMSS A.C.,
Original Article from The New England Journal of Medicine — Five-Year Survival with Combined Nivolumab and Ipilimumab in…
Original Article from The New England Journal of Medicine — Five-Year Survival with Combined Nivolumab and Ipilimumab in…
With a 5-year minimum follow-up in patients with metastatic melanoma, overall survival at 5 years was 52% with a combination of…
A new study is out in the New England Journal of Medicine called "Five-Year Survival with Combined Nivolumab and Ipilimumab in…
Zu den großen Fortschritten der neuen Medizin gehört die Entwicklung von Medikamenten gegen das fortgeschrittene Melanom (schwarz…
New 5-year survival data on the benefits of combination PD-1 + CTLA4 checkpoint blockade immunotherapy in patients with…
lqventures.com >>> ESMO19 Insights >>> Published by Boris Azais in Twitter: RT @NEJM: With a 5-year min follow-up, the…
lqventures.com >>> ESMO19 Insights >>> Published by MOC Brasil in Twitter: RT @MOCBrasil: Atualização do CheckMate067 no @NEJM…
lqventures.com >>> ESMO19 Insights >>> Published by Marciniak Lab in Twitter: RT @NEJM: With a 5-year min follow-up, the…
lqventures.com >>> ESMO19 Insights >>> Published by Enrique Bargallo R in Twitter: RT @NEJM: With a 5-year min follow-up, the…
lqventures.com >>> ESMO19 Insights >>> Published by Biotech-Catalyst in Twitter: RT @weoncologists: Live 📣from #ESMO19 @OncoAlert…
lqventures.com >>> ESMO19 Insights >>> Published by Biotech-Catalyst in Twitter: RT @AndyBiotech: Just 10 yrs ago, only 1 in 20…
lqventures.com >>> ESMO19 Insights >>> Published by Biotech-Catalyst in Twitter: RT @NEJM: With a 5-year min follow-up, the…
lqventures.com >>> ESMO19 Insights >>> Published by Mayra Perez in Twitter: RT @AndyBiotech: Just 10 yrs ago, only 1 in 20…
With a 5-year minimum follow-up, the combination of nivolumab plus ipilimumab was associated with 5-year survival of 52% in…